$GRTS
Gritstone Bio Inc
PRICE
$2.15 β²2.871%
Last Close
VOLUME
819,915
DAY RANGE
2.08 - 2.22
52 WEEK
2 - 14.42
Key Metrics
Market Cap
152.18 M
Beta
1.32
Avg. Volume
1.19 M
Shares Outstanding
72.81 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillarsβfirst, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patientβs immune system to specifically attack and destroy disease-causing cells. The companyβs lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an βoff-the-shelfβ shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.
CEO: Andrew Allen
Website: gritstonebio.com
HQ: 5858 Horton St Ste 210 Emeryville, 94608-2006 California
Related News